ST人福(600079.SH)拟定增募资30亿元至35亿元

Core Viewpoint - ST Renfu (600079.SH) announced a stock issuance to its controlling shareholder,招商生科, with the total fundraising amount expected to be no less than RMB 3 billion and no more than RMB 3.5 billion, aimed at various innovative drug development projects and working capital supplementation [1] Group 1 - The issuance is classified as a related party transaction [1] - The funds raised will be allocated to several projects, including the Yichang Renfu project, headquarters research institute project, and the construction of a complex formulation manufacturing base [1] - The net proceeds after deducting relevant issuance costs will be used for innovation drug R&D and digital construction projects [1]